SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SAT sets aside Sebi's order in Morepen Laboratories case

27 Apr 2021 Evaluate

The Securities Appellate Tribunal (SAT) has set aside regulator Sebi's order that had barred Morepen Laboratories from the capital markets for one year. Sebi, in September 2019, had prohibited Morepen Laboratories from the capital market for one year for making misleading disclosures about the issuance of global depository receipts (GDRs) way back in 2003. Pursuant to this, the company moved SAT against the order passed by the Securities and Exchange Board of India (Sebi).

Morepen Laboratories is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.

Morepen Laboratories Share Price

42.68 -0.31 (-0.72%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×